SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- BioLabs San Diego, Southern California’s premium coworking facility designed to help high-potential life-science startups go further, faster on limited capital investment, is now accepting applications for its new shared office space. Located at the Eastgate Campus in the University Towne Centre (UTC) area of San Diego, BioLabs is opening the space given the high demand from biotech startups. The 27,000 square-foot expansion space is designed for entrepreneurs seeking office space — as well as for early-stage companies that want all the benefits of being part of BioLabs’ creative bioinnovation ecosystem, but do not require the full wet-lab facilities offered in BioLabs San Diego’s original location.
Currently home to 32 early-stage life science companies, BioLabs San Diego is celebrating its second year of operations in San Diego and continues to make an impact in the market as the premier coworking space for life science startups. Since opening in 2016, BioLabs has helped more than 45 companies get started and grow and these companies have added more than 80 new jobs to the Southern California economy.
“We are very excited to be opening a second location in the Southern California biotech cluster, with expanded office spaces to enable digital health companies, distributed teams and virtual pharmaceutical companies, along with those who need to expand clinical operations to develop,” said BioLabs Founder Johannes Fruehauf, M.D., Ph.D. “After successful operations over the past two years, we are committed to growing the Southern California biotech footprint and providing services to amplify the network and resources for life science companies.”
Commenting on the second location, Susie Harborth, co-founder in San Diego and COO of BioLabs, said, “San Diego is home to some of the most innovative companies, yet there remains a need for private office spaces surrounded by peers in the industry; BioLabs is responding to a trending need in the community. We are excited about the expanded space because, with it, we will be able to help more entrepreneurs realize their visions. Through unique space offerings and exclusive, signature programming, the new space adds diversity to our portfolio of outstanding services.”
Members will have access to both BioLabs facilities in San Diego, at the Genesis campus (10210 Campus Point Drive, San Diego, California, 92121) for office and laboratory offerings or at the Eastgate campus (9620 Towne Centre Drive, San Diego, California, 92121) for team offices and event space. Biocom is a Founding Partner of BioLabs San Diego as are pharmaceutical partners: Novartis, Boehringer Ingelheim, Sanofi, Lilly, Takeda and Tosoh Corporation. Other sponsors include: Thermo Fisher Scientific, Eppendorf, Millipore Sigma, Wilson Sonsini Goodrich & Rosati, Cushman Wakefield, CRB, among others.
Cushman Wakefield represented BioLabs in its real estate expansion.
About BioLabs and BioLabs San Diego (www.biolabs.io twitter: @biolabsSD)
A membership-based network of shared laboratory facilities located in key geographies with proven biotech innovation clusters, BioLabs offers beautifully designed coworking environments that pair fully equipped and supported lab, office, and event spaces with relevant programming and unparalleled access to capital and industry partners. These fertile, supportive ecosystems allow young companies to shift their focus from startup operations to experimentation and innovation so they can reach their scientific potential quickly and achieve business success. Companies can start with a single lab bench and scale up as they grow. The expanding BioLabs network now comprises sites in Boston and Cambridge, Massachusetts; Durham, North Carolina; San Carlos, San Diego and San Francisco, California; New York City, and Princeton, New Jersey; and Philadelphia, Pennsylvania; and is developing sites with international partners as well.
Contact:
Caroline Grossman
Caroline@biolabs.io
781.771.5579
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/9c6416fc-a781-43a2-a4aa-05c083f2d231
http://www.globenewswire.com/NewsRoom/AttachmentNg/205a81fe-753b-47db-9bd8-f344fd43281e